Xylem

XYL · NYSE

$105.02+$1.49 (+1.44%)TodayMarket closed ·
Prev close $103.53

XYL analyst rating

BuyConsensus of 15 analysts over the last 12 months. 67% rate it a buy.
  • Strong buy0
  • Buy10
  • Hold5
  • Underperform0
  • Sell0

12-month price target · 18 analysts

Average $155.37 (+47.9% upside)

Low
$131.30
Now
$105.02
High
$180.60

Upgrades and downgrades

The latest rating actions, newest first

XYL analyst upgrades, downgrades and rating actions
FirmDateActionRating
JP MorganOct 19, 2026MaintainsNeutral
MizuhoOct 15, 2026MaintainsNeutral
OppenheimerOct 14, 2026MaintainsOutperform
RBC CapitalOct 14, 2026MaintainsOutperform
BarclaysOct 13, 2026MaintainsOverweight
CitigroupOct 12, 2026MaintainsBuy
UBSOct 5, 2026MaintainsNeutral
Wolfe ResearchSep 15, 2026InitiatesPeer Perform
JefferiesAug 24, 2026MaintainsBuy
UBSAug 13, 2026MaintainsNeutral

The case for and against

Updated Oct 16, 2026

Bull case

Xylem is supported by resilient end-market demand in water infrastructure, where recurring utility spending, outsourced water trends, and large-project wins such as the $850 million Dow contract and Miami-Dade AMI project should help offset near-term headwinds from China weakness and project timing delays. Its outlook is also strengthened by margin improvement levers, including 80/20 rationalization, mix shift toward higher-margin water meters, operating discipline, and accretive synergies from recent M&A such as TriOS, WaterFleet, and Cornell/Roper Pumps. With 2025 revenue at $9 billion, a 16,200-employee global footprint across 150+ countries, and substantial share repurchases alongside strategic capital deployment, the company appears positioned for improving earnings power and valuation re-rating.

Bear case

  • Xylem is facing a negative setup because its valuation and earnings outlook appear vulnerable if the favorable public utility and industrial water spending environment weakens, while management’s expected EPS for 2026/27E was still cut to $5.67/$6.25, signaling reduced confidence in near-term execution.
  • The company’s core profit drivers, including MCS and WSS, remain critical to the long-term story, yet underwhelming progress there or missteps in larger-scale M&A integration could pressure returns and limit the benefit from cross-selling and capital deployment.
  • Regulatory catalysts are also delayed, since the Advancing Water Reuse Act is unlikely to pass until after the midterm elections, pushing potential benefits into 2027 and beyond, while Xylem remains exposed to cyclical demand, macro weakness, interest rates, financing availability, and municipal or industrial spending volatility.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.